Curanex Pharmaceuticals (CURX) Payables (2024 - 2026)

Curanex Pharmaceuticals (CURX) has reported Payables for 3 consecutive years, with $154.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 42.75% year-over-year to $154.0; the trailing twelve-month figure through Jun 2026 stood at $154.0 (down 42.75% YoY), and the FY2025 full-year result was $2426.0, down 51.48% from the prior year.
• Payables slipped to $154.0 in Q2 2026 per CURX's latest filing, from $2426.0 in the prior quarter.
• Across five years, Payables topped out at $114489.0 in Q3 2025 and bottomed at $154.0 in Q2 2026.
• Historically, Payables has averaged $24467.6 across 3 years, with a median of $2426.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Payables tumbled 51.48% in 2025, then plunged 42.75% in 2026.
• Over 3 years, Payables stood at $5000.0 in 2024, then sank by 51.48% to $2426.0 in 2025, then slumped by 93.65% to $154.0 in 2026.
• According to Business Quant data, Payables over the past three periods registered $154.0, $2426.0, and $114489.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.